SCHEMBL29506482

SCHEMBL29506482

CN1CCN(c2ccc(Nc3ncc4c(n3)N3CCN=C3N(c3ccc(F)cc3Cl)C4=O)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WEE1 P30291 6/20 0.65
▸ NTRK1 P04629 1/20 0.48
▸ JAK2 O60674 2/20 0.47
▸ MAPK7 Q13164 2/20 0.47
▸ LRRK2 Q5S007 1/20 0.47
▸ CDK4 P11802 1/20 0.47
▸ CCND1 P24385 1/20 0.47
▸ SRC P12931 3/20 0.46
▸ FGFR1 P11362 1/20 0.46
▸ FGFR2 P21802 1/20 0.46
▸ FGFR4 P22455 1/20 0.46
▸ FGFR3 P22607 1/20 0.46
▸ BRD4 O60885 1/20 0.46
▸ MAPK8 P45983 1/20 0.45
▸ ALK Q9UM73 1/20 0.45
▸ CTSC P53634 1/20 0.45
▸ LCK P06239 1/20 0.45
▸ HCK P08631 1/20 0.45
▸ TNK2 Q07912 1/20 0.44
▸ FLT3 P36888 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21373353 1.00 WEE1 (0.65) WEE1NTRK1JAK2MAPK7LRRK2
SCHEMBL29506555 0.92 WEE1 (0.54) WEE1JAK2MAPK7LRRK2SRC
SCHEMBL21373340 0.92 WEE1 (0.54) WEE1JAK2MAPK7LRRK2SRC
SCHEMBL29506508 0.89 WEE1 (0.55) WEE1JAK2LRRK2SRCFGFR1
SCHEMBL20180608 0.89 WEE1 (0.55) WEE1JAK2LRRK2SRCFGFR1
SCHEMBL21373383 0.87 WEE1 (0.51) WEE1JAK2MAPK7LRRK2SRC
SCHEMBL29506544 0.87 WEE1 (0.51) WEE1JAK2MAPK7LRRK2SRC
SCHEMBL21373384 0.86 WEE1 (0.54) WEE1NTRK1JAK2LRRK2CDK4
SCHEMBL29506498 0.86 WEE1 (0.54) WEE1NTRK1JAK2LRRK2CDK4
SCHEMBL21373290 0.86 WEE1 (0.55) WEE1JAK2SRCFGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118338905-A Use of Wee1 kinase inhibitors in the treatment of cancer 上海瑛派药业有限公司 2024-07-12 — — CN claimed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN claimed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO claimed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO claimed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN claimed
WO-2025074275-A1 COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS AND WEE1 INHIBITORS REPARE THERAPEUTICS, INC. (CA) 2025-04-10 — — WO disclosed
CN-118338905-A Use of Wee1 kinase inhibitors in the treatment of cancer 上海瑛派药业有限公司 2024-07-12 — — CN disclosed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN disclosed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO disclosed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO disclosed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN disclosed
Send feedback